Tema Oncology ETF (NASDAQ:CANC) Sees Significant Decline in Short Interest

Tema Oncology ETF (NASDAQ:CANC) saw a significant decline in short interest during the month of October. As of October 30th, there was short interest totaling 3,276 shares, a decline of 69.1% from the October 15th total of 10,591 shares. Based on an average daily volume of 14,533 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the shares of the stock are short sold.

Tema Oncology ETF Stock Down 0.2%

Tema Oncology ETF stock traded down $0.07 during mid-day trading on Friday, reaching $41.14. 13,124 shares of the company’s stock traded hands, compared to its average volume of 30,022. Tema Oncology ETF has a 12-month low of $32.88 and a 12-month high of $47.00. The stock has a 50 day moving average of $41.63 and a two-hundred day moving average of $39.51. The company has a market cap of $210.23 million, a price-to-earnings ratio of 20.39 and a beta of 0.70.

Institutional Trading of Tema Oncology ETF

An institutional investor recently raised its stake in Tema Oncology ETF stock. Roxbury Financial LLC lifted its holdings in Tema Oncology ETF (NASDAQ:CANC) by 326.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,940 shares of the company’s stock after acquiring an additional 3,016 shares during the period. Roxbury Financial LLC owned 0.08% of Tema Oncology ETF worth $162,000 at the end of the most recent quarter.

Tema Oncology ETF Company Profile

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.